Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Jun;77(6):800-2.
doi: 10.1136/jnnp.2005.076869.

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

C Hirst, S Raasch, G Llewelyn, N Robertson
Case Reports

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)

C Hirst et al. J Neurol Neurosurg Psychiatry. 2006 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Van den Berg L H, Mollee I, Wokke J H.et al Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain‐Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 19955837–42. - PubMed
    1. Hughes R A, Swan A V, van Doorn P A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003(1)CD003280 - PubMed
    1. Briani C, Zara G, Zambello R.et al Rituximab‐responsive CIDP. Eur J Neurol 200411788 - PubMed
    1. Riechmann L, Clark M, Waldmann H.et al Reshaping human antibodies for therapy. Nature 1988332323–327. - PubMed
    1. Avivi I, Chakrabarti S, Kottaridis P.et al Neurological complications following alemtuzumab‐based reduced‐intensity allogeneic transplantation. Bone Marrow Transplant 200434137–142. - PubMed

MeSH terms